Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

The trial uncovered no new safety issues. New Delhi: Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight ...

Because they curb appetite, they can also support weight loss. More recently, tirzepatide, which targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, has received ...